HLA epitope based matching for transplantation

Transplant Immunology

Volumn 31, Issue 1, 2014, Pages 1-6

  Duquesnoy, René J ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Acceptable mismatch; Eplet; HLA antibody; HLA epitope; HLAMatchmaker; Permissible mismatch

Indexed keywords

EPITOPE; HLA ANTIBODY; HLA B ANTIGEN; HLA C ANTIGEN; HLA DR1 ANTIGEN; HLA DR2 ANTIGEN; HLA ANTIGEN;

ANTIBODY COMBINING SITE; ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ANTIGEN STRUCTURE; ANTIGENICITY; COMPLEMENTARITY DETERMINING REGION; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; CROSS REACTION; EDITORIAL; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; IMMUNOGENICITY; IMMUNOREACTIVITY; KIDNEY TRANSPLANTATION; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; INTERNET; PROCEDURES; REGISTER; TRANSPLANTATION;

EPITOPES; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; INTERNET; REGISTRIES; TRANSPLANTATION;

EID: 84903778859     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2014.04.004     Document Type: Editorial

References (89)

1. Duquesnoy R.J. HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. I. Description of the algorithm. Hum Immunol 2002, 63:339-352.
2. Duquesnoy R.J. A structurally based approach to determine HLA compatibility at the humoral immune level. Hum Immunol 2006, 67:847-862.
3. Duquesnoy R.J., Askar M. HLAMatchmaker: a molecularly based algorithm for histocompatibility determination V. Eplet matching for HLA-DR, HLA-DQ and HLA-DP. Hum Immunol 2007, 68:12-25.
4. Duquesnoy R.J., Mostecki J., Hariharan J., Balasz I. A structurally based epitope analysis of MICA antibody specificity patterns. Hum Immunol 2008, 69:826-832.
5. Duquesnoy R.J., Marrari M., da M., Sousa L.C.D., de M., Barroso J.R.P., et al. 16th IHIW: a website for the antibody-defined HLA epitope Registry. Int J Immunogenet 2013, 40:54-59.
6. Duquesnoy R.J., Marrari M., Mostecki J., da Mata Sousa L.C.D., do Monte S.J.H. First report on the antibody verification of MICA epitopes recorded in the HLA epitope registry. Int J Immunogenet 2014, [submitted for publication].
7. Duquesnoy R.J., Marrari M., Mulder A., da M., Sousa L.C.D., Da Silva A.S., et al. First report on the antibody verification of HLA-ABC epitopes recorded in the HLA epitope registry. Tissue Antigens 2014, [in press].
8. Duquesnoy R.J., Marrari M., Tambur A., da Mata Sousa L.C.D., do Monte S.J.H. First report on the antibody verification of HLA-DR, HLA-DQ and HLA-DP epitopes recorded in the HLA epitope registry. Hum Immunol 2014, [in press].
9. Sousa L.C.D.M., Sales H.L.A., Von Glehn C., Silva A.S., Santos Neto P.A., Castro J.A.F., et al. EpHLA: an innovative and user-friendly software automating the HLAMatchmaker algorithm for antibody analysis. Transpl Immunol 2011, 25:210-216.
10. Filho H., da Mata Sousa l, von Glehn C., da Silva A., dos Santos Neto P., do Nascimento F., et al. EpHLA software: a timesaving and accurate tool for improving identification of acceptable mismatches for clinical purposes. Transpl Immunol 2012, 26:230-234.
11. Duquesnoy R.J. Clinical usefulness of HLAMatchmaker in HLA epitope matching for organ transplantation. Curr Opin Immunol 2008, 20:594-601.
12. Duquesnoy R.J., Marrari M. HLAMatchmaker-based definition of structural HLA epitopes detected by alloantibodies. Curr Opin Transplant 2009, 14:403-409.
13. Duquesnoy R.J. Antibody-reactive epitope determination with HLAMatchmaker and its application in transplantation (review). Tissue Antigens 2011, 77:525-534.
14. Kabat E.A. The structural basis of antibody complementarity. Adv Protein Chem 1978, 32:1-75.
15. Chothia C., Lesk A., Tramontano A., Smith-Gill S., Air G., Sheriff S., et al. Conformation of immunoglobulin hypervariable regions. Nature 1989, 342:877-883.
16. Davies D., Padlan E., Sheriff S. Antibody-antigen complexes. Annu Rev Biochem 1990, 59:439-473.
17. MacCallum R.M., Martin A.C.R., Thornton J.M. Antibody-antigen interactions: contact analysis and binding site topography. J Mol Biol 1996, 262:732-745.
18. Getzoff E.D., Tainer J.A., Lerner R.A., Geysen H.M. The chemistry and mechanism of antibody binding to protein antigens. Adv Immunol 1988, 43:1-98.
19. Novotny J. Protein antigenicity: a thermodynamic approach. Mol Immunol 1991, 28:201-208.
20. Laune D., Molina K., Ferrieres G., Mani J.-C., Cohen P., Simon D., et al. Systematic exploration of the antigen binding activity of synthetic peptides isolated from the variable regions of immunoglobulins. J Biol Chem 1997, 272:30937-30944.
21. Van Regenmortel M. Reductionism and the search for structure-function relationships in antibody molecules. J Mol Recognit 2002, 15:240-247.
22. Duquesnoy R.J., Mulder A., Askar M., Fernandez-Vina M., Claas F.H.J. HLAMatchmaker-based analysis of human monoclonal antibody reactivity demonstrates the importance of an additional contact site for specific recognition of triplet-defined epitopes. Hum Immunol 2005, 66:749-761.
23. Marrari M., Mostecki J., Mulder A., Balazs I., Claas F., Duquesnoy R. Human monoclonal antibody reactivity with HLA Class I epitopes defined by pairs of mismatched eplets and self eplets. Transplantation 2010, 90:1468-1472.
24. Tambur A.R., Leventhal J.R., Friedewald J.J., Ramon D.S. The complexity of human leukocyte antigen (HLA)-DQ antibodies and its effect on virtual crossmatching. Transplantation 2010, 90:1117-1124.
25. Tambur A., Rosati J., Roitberg R., Glotz D., Friedewald J.J., Leventhal J.R. Epitope analysis of HLA-DQ antigens: what does the antibody see?. Transplantation 2014, [in press].
26. Duquesnoy R.J., Schaub S. Reactivity of HLA Class I epitope reactive antibodies induced during pregnancy 2014, [submitted for publication].
27. Barouch D., Davenport M., McMichael A., Reay P. A mAb against HLA-A2 can be influenced both positively and negatively by the associated peptide. Int Immunol 1995, 7:1599-1605.
28. Takamiya Y., Sakaguchi T., Miwa K., Takiguchi M. Role of HLA-B*5101 binding nonamer peptides in formation of the HLA-Bw4 public epitope. Int Immunol 1996, 8:1027-1034.
29. Sakaguchi T., Takamiya Y., Edidin M., Nokihara K., Miwa K., Schoenbach C., et al. Crucial role of N-terminal residue of binding peptides in recognition of the monoclonal antibody specific for the peptide-HLA-B5,-B35 complex. Immunogenetics 1998, 47:149-158.
30. Mulder M., Eijsink C., Kester M.G.D., Franke M.E.I., Kardol M.J., Heemskerk M.H.M., et al. Impact of peptides on the recognition of HLA Class I molecules by human HLA antibodies. J Immunol 2005, 175:5950-5957.
31. Duquesnoy R.J., Marrari M., Jelenik L., Zeevi A., Claas F.H.J., Mulder A. Structural aspects of HLA Class I epitopes reacting with human monoclonal antibodies in Ig-binding, C1q-binding and lymphocytotoxicity assays. Hum Immunol 2013, I74:1271-1279.
32. Lomago J., Jelenik L., Zern D., Howe J., Martell J., Zeevi A., et al. How did a patient who types for HLA-B*4403 develop antibodies that react with HLA-B*4402?. Hum Immunol 2010, 71:176-178.
33. Duquesnoy R.J., Marrari M. Detection of antibodies against HLA-C epitopes in patients with rejected kidney transplants. Transpl Immunol 2011, 24:164-171.
34. Marrari M., Duquesnoy R. Why can sensitization by a HLA-DR2 mismatch lead to antibodies that react also with HLA-DR1?. Hum Immunol 2009, 70:403-409.
35. Duquesnoy R.J., Awadalla Y., Lomago J., Jelinek L., Howe J., Zern D., et al. Retransplant candidates have donor-specific antibodies that react with structurally defined HLA-DR,DQ,DP epitopes. Transpl Immunol 2008, 18:352-360.
36. Duquesnoy R.J. HLA Class II antibodies and transplant outcome (invited editorial). Transplantation 2008, 86:638-640.
37. Tambur A., Leventhal J.R., Friedewald J., Ramon D. The complexity of human leukocyte antigen (HLA)-DQ antibodies and its effect on virtual crossmatching. Transplantation 2010, 90:1117-1124.
38. Zou Y., Qin Z., Silveus A., Fan Y., Stastny P. Polymorphisms of MICA recognized by human alloantibodies. Immunogenetics 2009, 61:91-100.
39. Claas F.H.J., Witvliet M., Duquesnoy R.J., Persijn G., Doxiadis I.I.N. The acceptable mismatch program as a fast tool to transplant highly sensitized patients awaiting a post-mortal kidney: short waiting time and excellent graft outcome. Transplantation 2004, 78:190-193.
40. Duquesnoy R.J., Witvliet M.J., Doxiadis I.I.N., de Fijter H., Claas F.H.J. HLAMatchmaker-based strategy to identify acceptable HLA Class I mismatches for highly sensitized kidney transplant candidates. Transpl Int 2004, 7:31-38.
41. Claas F.H.J., Dankers M.K., Oudshoorn M., van Rood J.J., Mulder A., Roelen D.L., et al. Differential immunogenicity of HLA mismatches in clinical transplantation. Transpl Immunol 2005, 14:187-191.
42. Goodman R.S., Taylor C.J., O'Rourke C.M., Lynch A., Bradley J.A., Key T. Utility of HLAMatchmaker and single-antigen HLA-antibody detection beads for identification of acceptable mismatches in highly sensitized patients awaiting kidney transplantation. Transplantation 2006, 81:1331-1336.
43. Doxiadis I.I.N., Duquesnoy R.J., Claas F.H.J. Extending options for highly sensitized patients to receive a suitable kidney graft. Curr Opin Immunol 2005, 17:536-540.
44. Iniotaki-Theodoraki A., Kalogeropoulou E., Apostolaki M., Doxiadis I., Stavropoulos-Giokas C. Humoral sensitization against rejected grafts: specific antibodies to graft immunogenic amino acid triplets. Transplant Proc 2004, 36:1728-1731.
45. Varnavidou-Nicolaidou A., Doxiadis I.I., Iniotaki-Theodoraki A., Patargias T., Stavropoulos-Giokas C., Kyriakides G.K., et al. HLA class I donor-specific triplet antibodies detected after renal transplantation. Transplant Proc 2004, 36:1732-1734.
46. Valentini R.P., Nehlsen-Cannarella S.L., Gruber S.A., Mattoo T.K., West M.S., Lang C., et al. Intravenous immunoglubulin, HLA allele typing and HLAMatchmaker facilitate successful transplantation in highly sensitized pediatric renal allograft recipients. Pediatr Transplant 2007, 11:77-81.
47. Nambiar A., Duquesnoy R.J., Adams S., Oblitas J., Leitman S., Stroncek D., et al. HLAMatchmaker-driven analysis of response to HLA matched platelet transfusions in alloimmunized patients. Blood 2006, 107:1680-1687.
48. Brooks E., MacPherson B., Fung M. Validation of HLAMatchmaker algorithm in identifying acceptable HLA mismatches for thrombocytopenic patients refractory to platelet transfusions. Transfusion 2008, 48:2159-2166.
49. Pai S.-C., Lo S.-C., Lin Tsai S.-J., Chang J.-S., Lin D.-T., Lin K.-S., et al. Epitope-based matching for HLA-alloimmunized platelet refractoriness in patients with hematologic diseases. Transfusion 2010, 50:2318-2327.
50. Dankers M.K.A., Witvliet M.D., Roelen D.L., De Lange P., Korfage N., Persijn G.G., et al. The number of amino acid triplet differences between patient and donor is predictive for the antibody reactivity against mismatched HLA antigens. Transplantation 2004, 77:1236-1239.
51. Mihaylova A., Baltadjieva D., Boneva P., Ivanova M., Penkova K., Marinova D., et al. Clinical relevance of anti-HLA antibodies detected by flow-cytometry bead-based assays-single-center experience. Hum Immunol 2006, 67:787-794.
52. Kosmoliaptsis V., Bradley J.A., Sharples L.D., Chaudhry A., Key T., Goodman R.S., et al. Predicting the immunogenicity of human leukocyte antigen class I alloantigens using structural epitope analysis determined by HLAMatchmaker. Transplantation 2008, 85:1817-1825.
53. Honger G., Fornaro I., Granado C., Tiercy J.M., Hosli I., Schaub S. Frequency and determinants of pregnancy-induced child-specific sensitization. Am J Transplant 2013, 13:746-753.
54. Wiebe C., Pochinco D., Blydt-Hansen T.D., Ho J., Birk P.E., Karpinsjki M., et al. Class II HLA epitope matching-a strategy to minimize de novo donor-specific antibody development and improve outcomes. Am J Transplant 2013, 20:1-9.
55. Duquesnoy R.J. Structural epitope matching for HLA alloimmunized thrombocytopenic patients: a new strategy to provide more effective platelet transfusion support?. Transfusion 2008, I48:221-227.
56. Duquesnoy R.J., Takemoto S., De Lange P., Doxiadis I.I.N., Schreuder G.M.T., Claas F.H.J. HLAMatchmaker: a molecularly based algorithm for histocompatibility determination III. Effect of matching at the HLA-A, B amino acid triplet level on kidney transplant survival. Transplantation 2003, 75:884-889.
57. Haririan A., Fagoaga O., Daneshvar H., Morawski K., Sillix D., El-Amm J., et al. Predictive value of HLA epitope matching using HLAMatchmaker for graft outcomes in a predominantly African-American renal transplant cohort. Clin Transpl 2006, 20:226-233.
58. Laux G., Mytilineos J., Opelz G. Critical evaluation of the amino acid triplet-epitope matching concept in cadaver kidney transplantation. Transplantation 2004, 77:902-907.
59. Duquesnoy R.J., Claas F. Is the application of HLAMatchmaker relevant in kidney transplantation? (Letter to the Editor). Transplantation 2005, 79:250-251.
60. Kosmoliaptsis V., Sharples L.D., Chaudhry A., Johnson R.J., Fuggle S.V., Halsall D.J., et al. HLA class I amino acid sequence-based matching after interlocus subtraction and long-term outcome after deceased donor kidney transplantation. Hum Immunol 2010, 71:851-856.
61. Laux G., Mansmann U., Deufel A., Opelz G. A new epitope-based HLA-DP matching approach for cadaveric kidney transplantation. Transplantation 2003, 75:1527-1532.
62. Duquesnoy R.J., Haagenson M., Spellman S., Wang T., Oudshoorn M. Triplet matching is not associated with better survival rates of patients with Class I HLA allele mismatched hematopoietic cell transplants from unrelated donors. Biol Blood Marrow Transplant 2008, 14:1064-1071.
63. Dankers M.K.A., Heemskerk M.H.M., RJ D., Doxiadis I., Oudshoorn M., Roelen D.L., et al. HLAMatchmaker algorithm is not a suitable tool predict the alloreactive cytotoxic T lymphocyte response in vitro. Transplantation 2004, 78:165-171.
64. Duquesnoy R.J., Claas F.H.J. Progress report of 14th international histocompatibility workshop project on the structural basis of HLA compatibility. Tissue Antigens 2007, 69(Suppl. 1):180-184.
65. Kosmoliaptsis V., Chaudhry A.N., Sharples L.D., Halsall D.J., Dafforn T.R., Bradley J.A., et al. Predicting HLA class I alloantigen immunogenicity from the number and physiochemical properties of amino acid polymorphisms. Transplantation 2009, 88:791-798.
66. Kosmoliaptsis V., Dafforn T.R., Chaudhry A.N., Halsall D.J., Bradley J.A., Taylor C.J. High-resolution, three-dimensional modeling of human leukocyte antigen class I structure and surface electrostatic potential reveals the molecular basis for alloantibody binding epitopes. Hum Immunol 2011, 72:1049-1059.
67. Burnet F., Fenner F. The production of antibodies 1949, Macmillan, Melbourne.
68. Burnet F. Self and not-self 1969, Melbourne Univ Press and Cambridge Univ Press.
69. Burnet F.M. The clonal selection theory of acquired immunity 1959, Cambridge Univ. Press, Cambridge,UK.
70. Jerne N. Towards a network theory of the immune system. Ann Inst Pasteur (Paris) 1974, 125:373-389.
71. Lederberg J. Genes and antibodies: do antigens bear instructions for antibody specificity or do they select cell lines that arise by mutation?. Science 1959, 129:1649-1653.
72. Janeway C. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today 1992, 13:11-16.
73. Tauber A. The immune self: theory or metaphor? 1994, Cambridge Univ Press, Cambridge, UK.
74. Silverstein A., Rose N. On the mystique of the immunological self. Immunol Rev 1997, 159:197-206.
75. Cohen I. The cognitive principle challenges clonal selection. Immunol Today 1992, 13:441-444.
76. Pradeu T., Carosella E. On the definition of a criterion of immunogenicity. Proc Natl Acad Sci U S A 2006, 103:17858-17861.
77. Cohn M., Mitchison N.A., Paul W., Silverstein A.M., Talmage D., Weigert M. Reflections on the clonal-selection theory. Nat Rev Immunol 2007, 7:823-830.
78. Tonegawa S. Somatic generation of antibody diversity. Nature 1983, 302:575-581.
79. Kim S., Davis M., Sinn E., Patten P., Hood L. Antibody diversity: somatic hypermutation of rearranged VH genes. Cell 1981, 27:573-581.
80. Wardemann H., Yurasov S., Schaefer A., Young J., Meffre E., Nussenzweig M. Predominant autoantibody production by early human B cell precursors. Science 2003, 301:1374-1377.
81. Nossal G., Pike B. Clonal anergy: persistence in tolerant mice of antigen-binding B lymphocytes incapable of responding to antigen or mitogen. Proc Natl Acad Sci U S A 1980, 77:1602-1606.
82. Hayakawa K., Asano M., Shinton S., Gui M., Allman D., Stewart C., et al. Positive selection of natural autoreactive B cells. Science 1999, 285:113-116.
83. Pillai S., Cariappa A., Moran S. Positive selection and lineage commitment during peripheral B-lymphocyte development. Immunol Rev 2004, 197:206-218.
84. Gay D., Saunders T., Camper S., Weigert M. Receptor editing: an approach by autoreactive B cells to escape tolerance. J Exp Med 1993, 177:999-1006.
85. Tiegs S., Russell D., Nemazee D. Receptor editing in self-reactive bone marrow B cells. J Exp Med 1993, 177:1009-1020.
86. Duquesnoy R.J. The antibody response to an HLA mismatch: a model for nonself-self discrimination in relation to HLA epitope immunogenicity. Int J Immunogenet 2011, 39:1-9.
87. Marrari M., Conca R., Praticò-Barbato L., Amoroso A., Duquesnoy R. Brief report: why did two patients who type for HLA-B13 have antibodies that react with all Bw4 antigens except HLA-B13?. Transpl Immunol 2011, 25:217-220.
88. Duquesnoy R.J., White L.T., Fierst J.W., Vanek M., Banner B.F., Iwaki Y., et al. Multiscreen serum analysis of highly sensitized renal dialysis patients for antibodies toward public and private class I HLA determinants. Implications for computer-predicted acceptable and unacceptable donor mismatches in kidney transplantation. Transplantation 1990, 50:427-437.
89. Rodey G.E., Neylan J.F., Whelchel J.D., Revels K.W., Bray R.A. Epitope specificity of HLA class I alloantibodies. I. Frequency analysis of antibodies to private versus public specificities in potential transplant recipients. Hum Immunol 1994, 39:272-280.